Register entry

TerSera Therapeutics LLC

Registered sites
0
Drug products
9
Live patents
20
Countries
0
Base
Unknown
Sites

Facilities

0

No registered facilities

This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.

Exclusivity

Patents

20

Unexpired Orange Book patents where this company is the application holder.

ProductActive ingredientExpiry
QMIIZ ODTMELOXICAMAug 2030
VARUBIROLAPITANT HYDROCHLORIDEApr 2027
VARUBIROLAPITANT HYDROCHLORIDEAug 2028
VARUBIROLAPITANT HYDROCHLORIDEJan 2029
VARUBIROLAPITANT HYDROCHLORIDEOct 2029
VARUBIROLAPITANT HYDROCHLORIDEJul 2032
XERMELOTELOTRISTAT ETIPRATEDec 2027
XERMELOTELOTRISTAT ETIPRATEDec 2028
XERMELOTELOTRISTAT ETIPRATEFeb 2031
XERMELOTELOTRISTAT ETIPRATEFeb 2031
Catalogue

Marketed products

9

Showing 9 of 9.

BrandGeneric nameFormCategory
MARGENZAmargetuximab-cmkbINJECTION, SOLUTION, CONCENTRATEBLA
PRIALTziconotide acetateINJECTION, SOLUTIONNDA
PRIALTziconotide acetateINJECTION, SOLUTIONNDA
PRIALTziconotide acetateINJECTION, SOLUTIONNDA
QUZYTTIRCetirizine HydrochlorideINJECTIONNDA
VarubirolapitantTABLETNDA
Xermelotelotristat ethylTABLETNDA
ZOLADEXgoserelinIMPLANTNDA
ZOLADEXgoserelinIMPLANTNDA
Provenance

Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.